JP4742752B2 - Beverage production method - Google Patents
Beverage production method Download PDFInfo
- Publication number
- JP4742752B2 JP4742752B2 JP2005249681A JP2005249681A JP4742752B2 JP 4742752 B2 JP4742752 B2 JP 4742752B2 JP 2005249681 A JP2005249681 A JP 2005249681A JP 2005249681 A JP2005249681 A JP 2005249681A JP 4742752 B2 JP4742752 B2 JP 4742752B2
- Authority
- JP
- Japan
- Prior art keywords
- tea
- caffeine
- tea leaves
- hot water
- beverage
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 235000013361 beverage Nutrition 0.000 title claims description 50
- 238000004519 manufacturing process Methods 0.000 title claims description 19
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 claims description 114
- 235000013616 tea Nutrition 0.000 claims description 93
- 244000269722 Thea sinensis Species 0.000 claims description 91
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 67
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 claims description 57
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 claims description 57
- 229960001948 caffeine Drugs 0.000 claims description 57
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims description 52
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 claims description 43
- 235000005487 catechin Nutrition 0.000 claims description 43
- 238000000034 method Methods 0.000 claims description 18
- 235000006408 oxalic acid Nutrition 0.000 claims description 17
- 239000000284 extract Substances 0.000 claims description 16
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 claims description 13
- 229950001002 cianidanol Drugs 0.000 claims description 13
- 150000003839 salts Chemical class 0.000 claims description 13
- 239000000203 mixture Substances 0.000 claims description 8
- 235000018553 tannin Nutrition 0.000 claims description 6
- 229920001864 tannin Polymers 0.000 claims description 6
- 239000001648 tannin Substances 0.000 claims description 6
- 229940092665 tea leaf extract Drugs 0.000 claims description 6
- 235000009569 green tea Nutrition 0.000 claims description 5
- 230000008569 process Effects 0.000 claims description 5
- 241001423651 Buchnera americana Species 0.000 claims description 4
- 244000020518 Carthamus tinctorius Species 0.000 claims description 2
- 235000003255 Carthamus tinctorius Nutrition 0.000 claims description 2
- 235000008429 bread Nutrition 0.000 claims description 2
- 150000001765 catechin Chemical class 0.000 description 34
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 16
- 238000012360 testing method Methods 0.000 description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- 230000003266 anti-allergic effect Effects 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 230000002401 inhibitory effect Effects 0.000 description 9
- 238000012545 processing Methods 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- 229960001340 histamine Drugs 0.000 description 8
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 5
- 208000008589 Obesity Diseases 0.000 description 5
- 235000020824 obesity Nutrition 0.000 description 5
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 230000002378 acidificating effect Effects 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 239000004927 clay Substances 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 235000019634 flavors Nutrition 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 4
- -1 organic acid salts Chemical class 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 206010029216 Nervousness Diseases 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 208000026935 allergic disease Diseases 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- XMOCLSLCDHWDHP-IUODEOHRSA-N epi-Gallocatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-IUODEOHRSA-N 0.000 description 3
- 210000003630 histaminocyte Anatomy 0.000 description 3
- 238000010335 hydrothermal treatment Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 229920000139 polyethylene terephthalate Polymers 0.000 description 3
- 239000005020 polyethylene terephthalate Substances 0.000 description 3
- 150000008442 polyphenolic compounds Chemical class 0.000 description 3
- 235000013824 polyphenols Nutrition 0.000 description 3
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 238000004659 sterilization and disinfection Methods 0.000 description 3
- WVRDOLPMKOCJRJ-DENIHFKCSA-N (-)-Epigallocatechin 3-(3-methyl-gallate) Chemical compound OC1=C(O)C(OC)=CC(C(=O)O[C@H]2[C@H](OC3=CC(O)=CC(O)=C3C2)C=2C=C(O)C(O)=C(O)C=2)=C1 WVRDOLPMKOCJRJ-DENIHFKCSA-N 0.000 description 2
- BMJHAAZDURGGSC-TZIWHRDSSA-N (-)-Epigallocatechin 3-(4-methyl-gallate) Chemical compound C1=C(O)C(OC)=C(O)C=C1C(=O)O[C@H]1[C@@H](C=2C=C(O)C(O)=C(O)C=2)OC2=CC(O)=CC(O)=C2C1 BMJHAAZDURGGSC-TZIWHRDSSA-N 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 2
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 235000009024 Ceanothus sanguineus Nutrition 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 102000000646 Interleukin-3 Human genes 0.000 description 2
- 108010002386 Interleukin-3 Proteins 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- XMOCLSLCDHWDHP-UHFFFAOYSA-N L-Epigallocatechin Natural products OC1CC2=C(O)C=C(O)C=C2OC1C1=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-UHFFFAOYSA-N 0.000 description 2
- 239000002211 L-ascorbic acid Substances 0.000 description 2
- 235000000069 L-ascorbic acid Nutrition 0.000 description 2
- 240000003553 Leptospermum scoparium Species 0.000 description 2
- 235000015459 Lycium barbarum Nutrition 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 208000005374 Poisoning Diseases 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 230000000172 allergic effect Effects 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 235000019658 bitter taste Nutrition 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 238000013124 brewing process Methods 0.000 description 2
- 235000015165 citric acid Nutrition 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 235000012734 epicatechin Nutrition 0.000 description 2
- DZYNKLUGCOSVKS-UHFFFAOYSA-N epigallocatechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3cc(O)c(O)c(O)c3 DZYNKLUGCOSVKS-UHFFFAOYSA-N 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 235000013376 functional food Nutrition 0.000 description 2
- LVJJFMLUMNSUFN-UHFFFAOYSA-N gallocatechin gallate Natural products C1=C(O)C=C2OC(C=3C=C(O)C(O)=CC=3)C(O)CC2=C1OC(=O)C1=CC(O)=C(O)C(O)=C1 LVJJFMLUMNSUFN-UHFFFAOYSA-N 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 229940076264 interleukin-3 Drugs 0.000 description 2
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000004811 liquid chromatography Methods 0.000 description 2
- 239000001630 malic acid Substances 0.000 description 2
- 235000011090 malic acid Nutrition 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 231100000572 poisoning Toxicity 0.000 description 2
- 230000000607 poisoning effect Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 230000001953 sensory effect Effects 0.000 description 2
- 239000011755 sodium-L-ascorbate Substances 0.000 description 2
- 235000019187 sodium-L-ascorbate Nutrition 0.000 description 2
- 238000005507 spraying Methods 0.000 description 2
- 238000010025 steaming Methods 0.000 description 2
- 238000000859 sublimation Methods 0.000 description 2
- 230000008022 sublimation Effects 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- XMOCLSLCDHWDHP-SWLSCSKDSA-N (+)-Epigallocatechin Natural products C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-SWLSCSKDSA-N 0.000 description 1
- LSHVYAFMTMFKBA-PZJWPPBQSA-N (+)-catechin-3-O-gallate Chemical compound O([C@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=CC=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 LSHVYAFMTMFKBA-PZJWPPBQSA-N 0.000 description 1
- PFTAWBLQPZVEMU-ZFWWWQNUSA-N (+)-epicatechin Natural products C1([C@@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-ZFWWWQNUSA-N 0.000 description 1
- WMBWREPUVVBILR-GHTZIAJQSA-N (+)-gallocatechin gallate Chemical compound O([C@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-GHTZIAJQSA-N 0.000 description 1
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 description 1
- PFTAWBLQPZVEMU-UKRRQHHQSA-N (-)-epicatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-UKRRQHHQSA-N 0.000 description 1
- LSHVYAFMTMFKBA-TZIWHRDSSA-N (-)-epicatechin-3-O-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=CC=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 LSHVYAFMTMFKBA-TZIWHRDSSA-N 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- BDOYKFSQFYNPKF-UHFFFAOYSA-N 2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid;sodium Chemical compound [Na].[Na].OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O BDOYKFSQFYNPKF-UHFFFAOYSA-N 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- CXRFDZFCGOPDTD-UHFFFAOYSA-M Cetrimide Chemical compound [Br-].CCCCCCCCCCCCCC[N+](C)(C)C CXRFDZFCGOPDTD-UHFFFAOYSA-M 0.000 description 1
- CIWBSHSKHKDKBQ-DUZGATOHSA-N D-araboascorbic acid Natural products OC[C@@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-DUZGATOHSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 description 1
- LSHVYAFMTMFKBA-UHFFFAOYSA-N ECG Natural products C=1C=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 LSHVYAFMTMFKBA-UHFFFAOYSA-N 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- BXDRTHBTGNNTEW-NHCUHLMSSA-N Epicatechin 3-O-(4-methylgallate) Chemical compound C1=C(O)C(OC)=C(O)C=C1C(=O)O[C@H]1[C@@H](C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1 BXDRTHBTGNNTEW-NHCUHLMSSA-N 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000002705 Glucose Intolerance Diseases 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 235000005135 Micromeria juliana Nutrition 0.000 description 1
- 244000294411 Mirabilis expansa Species 0.000 description 1
- 235000015429 Mirabilis expansa Nutrition 0.000 description 1
- 206010028735 Nasal congestion Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 206010039101 Rhinorrhoea Diseases 0.000 description 1
- 240000002114 Satureja hortensis Species 0.000 description 1
- 235000007315 Satureja hortensis Nutrition 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 230000002058 anti-hyperglycaemic effect Effects 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 230000003579 anti-obesity Effects 0.000 description 1
- 239000000043 antiallergic agent Substances 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 238000005251 capillar electrophoresis Methods 0.000 description 1
- 239000003729 cation exchange resin Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000001877 deodorizing effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 108010042617 dinitrophenyl-human serum albumin conjugate Proteins 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- LPTRNLNOHUVQMS-UHFFFAOYSA-N epicatechin Natural products Cc1cc(O)cc2OC(C(O)Cc12)c1ccc(O)c(O)c1 LPTRNLNOHUVQMS-UHFFFAOYSA-N 0.000 description 1
- XGTBMCGGGJLOPS-IFMALSPDSA-N epicatechin 3-O-(3'-O-methylgallate) Chemical compound OC1=C(O)C(OC)=CC(C(=O)O[C@H]2[C@H](OC3=CC(O)=CC(O)=C3C2)C=2C=C(O)C(O)=CC=2)=C1 XGTBMCGGGJLOPS-IFMALSPDSA-N 0.000 description 1
- 229940030275 epigallocatechin gallate Drugs 0.000 description 1
- 235000010350 erythorbic acid Nutrition 0.000 description 1
- 239000004318 erythorbic acid Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- DNJIEGIFACGWOD-UHFFFAOYSA-N ethyl mercaptane Natural products CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 1
- 230000002964 excitative effect Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 description 1
- 229940107187 fructooligosaccharide Drugs 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 235000021255 galacto-oligosaccharides Nutrition 0.000 description 1
- 150000003271 galactooligosaccharides Chemical class 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 229940026239 isoascorbic acid Drugs 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 235000013536 miso Nutrition 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 208000010753 nasal discharge Diseases 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000002985 plastic film Substances 0.000 description 1
- 229920006255 plastic film Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 201000009104 prediabetes syndrome Diseases 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 206010041232 sneezing Diseases 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 1
- 235000010378 sodium ascorbate Nutrition 0.000 description 1
- 229960005055 sodium ascorbate Drugs 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- PXLIDIMHPNPGMH-UHFFFAOYSA-N sodium chromate Chemical compound [Na+].[Na+].[O-][Cr]([O-])(=O)=O PXLIDIMHPNPGMH-UHFFFAOYSA-N 0.000 description 1
- 239000004320 sodium erythorbate Substances 0.000 description 1
- 235000010352 sodium erythorbate Nutrition 0.000 description 1
- RBWSWDPRDBEWCR-RKJRWTFHSA-N sodium;(2r)-2-[(2r)-3,4-dihydroxy-5-oxo-2h-furan-2-yl]-2-hydroxyethanolate Chemical compound [Na+].[O-]C[C@@H](O)[C@H]1OC(=O)C(O)=C1O RBWSWDPRDBEWCR-RKJRWTFHSA-N 0.000 description 1
- 239000008234 soft water Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- FYIJLTSMNXUNLT-CXQFPWCTSA-N strictinin Chemical compound O([C@@H]1O[C@@H]2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)O[C@H]2[C@H](O)[C@H]1O)C(=O)C1=CC(O)=C(O)C(O)=C1 FYIJLTSMNXUNLT-CXQFPWCTSA-N 0.000 description 1
- FYIJLTSMNXUNLT-RXRHLBNPSA-N strictinin Natural products O=C(O[C@@H]1[C@@H](O)[C@H](O)[C@H]2OC(=O)c3c(c(O)c(O)c(O)c3)-c3c(O)c(O)c(O)cc3C(=O)OC[C@@H]2O1)c1cc(O)c(O)c(O)c1 FYIJLTSMNXUNLT-RXRHLBNPSA-N 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 235000019583 umami taste Nutrition 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Images
Landscapes
- Tea And Coffee (AREA)
Description
本発明は、カフェイン含有量が低減された飲料及びその製造方法に関し、より詳しくは生茶葉を所定の条件で処理を行い茶葉中のカフェイン含有量を低減させた茶葉の抽出物を含む飲料及びその製造方法に関する。 The present invention relates to a beverage having a reduced caffeine content and a method for producing the same, and more specifically, a beverage comprising a tea leaf extract in which fresh tea leaves are treated under predetermined conditions to reduce the caffeine content in the tea leaves. And a manufacturing method thereof.
近年、食生活の高脂肪・高カロリー化により、国民の肥満化が進行している。上半身肥満、耐糖能異常、高中性脂肪、高血圧は「死の四重奏」と呼ばれ、これらが重なると加速度的に動脈硬化や心疾患の曜患率が高まり、生命を脅かすとされている。このような生理学的異常の発現には、遺伝因子とともに食生活をはじめとする環境因子が大きく関わっているため、予防・改善するためには時として生活習慣を大きく変える必要があり、持続困難な自己規制を強いられることがある。誰もが受け入れられるような簡便な肥満の予防もしくは改善手段が望まれている。 In recent years, the obesity of the people has progressed due to the high fat and high calorie content of the diet. Upper body obesity, impaired glucose tolerance, high triglycerides, and high blood pressure are called “death quartet”. When they overlap, the rate of atherosclerosis and heart disease increases at an accelerated rate and is considered life-threatening. The manifestation of such physiological abnormalities is greatly related to genetic factors and environmental factors such as dietary habits, so it is sometimes necessary to change lifestyle habits to prevent or improve, and it is difficult to sustain. You may be forced to self-regulate. A simple means of preventing or improving obesity that anyone can accept is desired.
また、過度の免疫反応の一つであるアレルギーは、植物、動物、微生物、食物、化学物質などの「アレルゲン」と呼ばれる原因物質により発症する。特にアレルギー性鼻炎は、花粉症に代表される上気道アレルギー疾患であり、くしゃみ発作、水性鼻汁、鼻閉などの症状を示す。日本全国で花粉症患者だけでも1300万人といわれており、大きな社会問題となっている。アレルギー症状を抑制するためには、ヒスタミン等アレルギー症状を引き起こす化学伝達性物質が、マスト細胞から放出されることを抑制する必要がある。このヒスタミン放出を抑制するために、抗アレルギー剤の開発が望まれている。 In addition, allergies, which are one of excessive immune reactions, are caused by causative substances called “allergens” such as plants, animals, microorganisms, foods, and chemical substances. In particular, allergic rhinitis is an upper respiratory tract allergic disease represented by hay fever, and exhibits symptoms such as sneezing attacks, aqueous nasal discharge, and nasal congestion. It is said that there are 13 million hay fever patients all over Japan, which is a big social problem. In order to suppress allergic symptoms, it is necessary to suppress the release of chemotransmitters that cause allergic symptoms such as histamine from mast cells. In order to suppress this histamine release, development of an antiallergic agent is desired.
このような問題を解決するために、食品又はこれに準ずる天然物から様々な有用物質が見出され、その生理機能を生かした機能性食品の研究が盛んに行なわれている。機能性食品は、健常な人が日常的に摂取することで血液脂質、血糖値、血圧、アレルギー疾患等の改善が期待され、簡便な健康増進・疾病予防手段を提供するものである。中でも特に、肥満の予防もしくは改善作用が期待される素材としてはポリフェノール類が注目を集めつつあり、中でも緑茶由来のカテキン類は最も研究が進んでいる素材に数えられる。 In order to solve such problems, various useful substances have been found in foods or similar natural products, and functional foods that make use of their physiological functions have been actively studied. Functional foods are expected to improve blood lipids, blood sugar levels, blood pressure, allergic diseases and the like when taken by a healthy person on a daily basis, and provide simple means for promoting health and preventing diseases. In particular, polyphenols are attracting attention as materials that are expected to prevent or improve obesity, and among them, catechins derived from green tea are among the most studied materials.
カテキン類とは緑茶特有のタンニン又はポリフェノールの一種であり、緑茶の味を決める主成分の一つである。このカテキン類は、抗酸化作用、動脈硬化抑制作用、血圧上昇抑制作用、血糖上昇抑制作用、抗アレルギー作用、抗菌作用等、多様な作用があることが実証されているため、茶葉の粉末等を健康食品の原料に用いることによって、基礎代謝を向上させ、脂肪の燃焼を促進させることによって肥満を予防する方法が知られている(非特許文献1)。カテキン類のこのような生理効果を発現させるには、成人一日あたり4杯から5杯のお茶を飲むことが必要である。このため、より簡便に大量のカテキン類を摂取できるよう、飲料にカテキン類を高濃度に配合する技術が望まれている。 Catechins are a kind of tannin or polyphenol unique to green tea, and are one of the main components that determine the taste of green tea. These catechins have been demonstrated to have various effects such as antioxidant, arteriosclerotic, antihypertensive, antihyperglycemic, antiallergic, antibacterial, etc. A method for preventing obesity by improving basal metabolism and promoting fat burning by using it as a raw material for health food is known (Non-patent Document 1). In order to develop such physiological effects of catechins, it is necessary to drink 4 to 5 cups of tea per day for adults. For this reason, the technique of mix | blending catechins with high concentration in a drink is desired so that a large amount of catechins can be ingested more simply.
また、ポリフェノール中、エピガロカテキン−3−O−(3−O−メチル)ガレート、エピガロカテキン−3−O−(4−O−メチル)ガレート等のメチル化されたメチル化カテキンは、強い抗アレルギー効果を持つことが知られており、メチル化カテキンが含有されている飲食品に対する需要が高まっている。 Further, in polyphenol, methylated methylated catechins such as epigallocatechin-3-O- (3-O-methyl) gallate and epigallocatechin-3-O- (4-O-methyl) gallate are strong. It is known to have an antiallergic effect, and there is an increasing demand for foods and drinks containing methylated catechins.
しかし、茶葉中にはカテキン類が約8%から15%含まれているものの、カフェインも通常2%から4%含まれている。カフェインは中枢神経興奮作用を奏することから、眠気抑制に使用されている反面、過剰摂取による神経過敏、吐き気、不眠などの有害作用を引き起こす原因にもなる。このため、カフェイン含有組成物から、カフェインのみを選択的に除去する方法が検討されてきた(特許文献1,2参照)。
特許文献1に記載のタンニン類の製造方法は、茶葉抽出液を陽イオン交換樹脂に接触させた後、その処理液を多孔質性の樹脂と接触させている。これによって、茶葉抽出物中のカフェインが除去されたものを提供することができる。また、多孔質性の樹脂にはタンニン類(カテキン類)が吸着するため、カテキン類のみを単離することができる。しかし、この方法ではカフェインのみを選択的に除去するのではなく、有効成分であるカテキン類の組成も変化してしまうという可能性がある。また、特許文献2には、カフェインを含有する水溶液を活性白土又は酸性白土と接触させる方法が開示されている。これによって、選択的にカフェインを除去することが可能となる。しかしながら、活性白土又は酸性白土を使用するため、色相が悪化してしまう場合があり、見た目の色によって消費者の購買欲が左右される飲料への使用には適さない。
In the method for producing tannins described in
また、上記のどちらの方法も、茶葉の抽出物を用いて何らかの処理を施しているため、茶葉から工業的に飲料を製造する場合において、既存の製造ラインの途中に上記の処理を施す工程を組み込む必要がある。そのため、プロセス上の設備負荷が過大であり、工業レベルの実施において簡易性に欠ける。 In addition, since both of the above methods perform some processing using the tea leaf extract, the step of performing the above processing in the middle of an existing production line in the case of industrially producing beverages from tea leaves. Must be included. Therefore, the equipment load on the process is excessive, and lack of simplicity in industrial level implementation.
本発明は以上のような課題に鑑みてなされたものであり、その目的は、茶葉の生葉に含まれているカテキン類の含有量を保持しながらカフェインの含有量を低減するのに有効な製法を開発し、それによって、カフェインによる害が低減されている荒茶や仕上げ茶の茶抽出物を使用した飲料及びその製造方法を提供することである。 The present invention has been made in view of the problems as described above, and its purpose is effective in reducing the content of caffeine while maintaining the content of catechins contained in the raw leaves of tea leaves. To develop a manufacturing method, thereby providing a beverage using a tea extract of crude tea or finished tea in which the damage caused by caffeine is reduced, and a manufacturing method thereof.
より具体的には、本発明は以下のようなものを提供する。 More specifically, the present invention provides the following.
(1) 採取した生茶葉中のカフェイン濃度が熱水処理前の60質量%以下であり、かつ、シュウ酸又はその塩の濃度が熱水処理前の95質量%以下、になるまで熱水処理を行って得られた被処理茶葉からなる荒茶の抽出物を含む飲料。 (1) Hot water until the concentration of caffeine in the collected fresh tea leaves is 60% by mass or less before the hot water treatment and the concentration of oxalic acid or a salt thereof is 95% by mass or less before the hot water treatment A beverage containing an extract of crude tea made of treated tea leaves obtained by processing.
カフェインは熱水によく溶け昇華性を有する。昇華は約120℃程度から開始するが、熱水処理を行なうことにより、常圧で120℃よりも低い温度でカフェインを茶葉から抽出することができる。また、シュウ酸又はその塩はカリウム塩やカルシウム塩の形で植物細胞中に存在し、水に対する溶解性を有しているため常温の水に対しても比較的高い溶解度を有する。従って、熱水処理を行なうことにより、茶葉から容易に除去することができる。一方、カテキン類の水に対する溶解性は低い。従って(1)の発明によれば、生茶葉に熱水処理を施すことによって、茶葉中のカフェイン濃度を約60%程度低減させることができる。 Caffeine dissolves well in hot water and has sublimation properties. Sublimation starts at about 120 ° C., but by performing hot water treatment, caffeine can be extracted from tea leaves at a temperature lower than 120 ° C. at normal pressure. Moreover, oxalic acid or a salt thereof is present in plant cells in the form of potassium salt or calcium salt, and has solubility in water, and therefore has relatively high solubility in water at room temperature. Therefore, it can be easily removed from tea leaves by performing hot water treatment. On the other hand, the solubility of catechins in water is low. Therefore, according to the invention of (1), the caffeine concentration in the tea leaves can be reduced by about 60% by subjecting the fresh tea leaves to hot water treatment.
また、カフェインは茶飲料に通常、80mg/100ml程度含有されている。カフェインを2時間以内に300mg以上(カップ4杯程度)摂取した場合、不安感を伴う神経過敏性等のカフェイン中毒症状を引き起こす場合がある。従って、(1)の発明によりカフェイン濃度を約60%程度低減させることができればカフェイン中毒症状の発生を防止することができ、かつ、乳幼児やカフェイン感受性の人でも手軽に飲むことができる茶飲料を提供することが可能となる。 In addition, caffeine is usually contained in tea beverages at about 80 mg / 100 ml. Ingestion of 300 mg or more (about 4 cups) of caffeine within 2 hours may cause caffeine poisoning symptoms such as nervousness with anxiety. Therefore, if the caffeine concentration can be reduced by about 60% according to the invention of (1), the occurrence of caffeine poisoning can be prevented, and even an infant or a caffeine sensitive person can easily take it. It becomes possible to provide a tea beverage.
更にシュウ酸又はその塩は、茶葉においては苦味やえぐみの成分となるため、(1)の発明によりシュウ酸又はその塩が選択的に除去されることにより、さっぱりとした嗜好性の高い飲料を提供することが可能となる。なお、シュウ酸又はその塩の茶葉中の含有量は、玉露上級で1.29%、玉露下級で1.17%、煎茶上級で0.82%、煎茶下級で0.95%、番茶で0.74%、ほうじ茶で0.77%である。 Furthermore, since oxalic acid or a salt thereof becomes a bitter or savory component in tea leaves, the oxalic acid or a salt thereof is selectively removed by the invention of (1), so that a refreshing and highly palatable beverage can be obtained. It becomes possible to provide. The content of oxalic acid or its salt in tea leaves was 1.29% for Gyokuro Advanced, 1.17% for Gyokuro Junior, 0.82% for Sencha Advanced, 0.95% for Sencha Junior, 0 for Bancha .74% and Hojicha 0.77%.
(2) 前記生茶葉中の総カテキン濃度と、前記被処理茶葉中の総カテキン濃度との差は、0.1質量%から5質量%である(1)に記載の飲料。 (2) The beverage according to (1), wherein the difference between the total catechin concentration in the fresh tea leaves and the total catechin concentration in the treated tea leaves is 0.1% by mass to 5% by mass.
上述のようにカテキン類の水に対する溶解性は低く、茶葉に対して熱水処理を行なっても容易に除去することはできない。従って(2)の発明によればカフェイン及びシュウ酸等の濃度が低減され、かつ、カテキン類の濃度がほとんど低減されていない飲料を提供することができる。 As described above, the solubility of catechins in water is low, and it cannot be easily removed even if hot water treatment is performed on tea leaves. Therefore, according to the invention of (2), it is possible to provide a beverage in which the concentrations of caffeine and oxalic acid are reduced and the concentration of catechins is hardly reduced.
また、カテキン類は、抗アレルギー作用、抗酸化作用、動脈硬化抑制作用、血圧上昇抑制作用、血糖上昇抑制作用、殺菌作用、抗菌作用、消臭作用等様々な効果を有する。しかし、従来のカテキンが高濃度含有された飲料には、カフェインも高濃度で含有されている。そのため、乳幼児やカフェイン感受性の人は飲むことができず、カテキン類が有している有用な効果を享受することができなかった。しかし(2)の発明によれば、乳幼児等でも安心して摂取することができる。 In addition, catechins have various effects such as antiallergic action, antioxidant action, arteriosclerosis inhibiting action, blood pressure rise inhibiting action, blood sugar rise inhibiting action, bactericidal action, antibacterial action, and deodorizing action. However, beverages containing a high concentration of conventional catechins also contain caffeine at a high concentration. For this reason, infants and caffeine-sensitive persons cannot drink and cannot enjoy the useful effects of catechins. However, according to the invention of (2), even infants and the like can take in peace.
ここで、カテキン類とは、カテキン、ガロカテキン、カテキンガレート、ガロカテキンガレートなどの非エピ体カテキン類及びエピカテキン、エピガロカテキン、エピカテキンガレート、エピガロカテキンガレートなどのエピ体カテキン類等をいう。 Here, the catechins refer to non-epimeric catechins such as catechin, gallocatechin, catechin gallate, gallocatechin gallate, and epicatechins such as epicatechin, epigallocatechin, epicatechin gallate, epigallocatechin gallate, and the like. .
(3) 前記荒茶の抽出物中の総カテキン量とカフェイン量との除数は、4から50である(1)又は(2)に記載の飲料。 (3) The beverage according to (1) or (2), wherein a divisor between the total catechin amount and the caffeine amount in the crude tea extract is 4 to 50.
カフェインに対するカテキン類の割合が低すぎると、クリームダウンなどの濁りを生じるため外観を害し好ましくないだけでなく、カフェインの過剰摂取の危険性がある。またカフェインに対する非重合体カテキン類の比率が高すぎると、風味バランス上好ましくない。従って(3)の発明によれば、荒茶の抽出物中の総カテキン量とカフェイン量との除数を上記値としたことによって風味のバランスが良い飲料を提供することができる。 If the ratio of catechins to caffeine is too low, it causes turbidity such as cream down, which is unfavorable in appearance and unfavorable, and there is a risk of excessive consumption of caffeine. Moreover, when the ratio of the non-polymer catechins to caffeine is too high, it is not preferable in terms of flavor balance. Therefore, according to the invention of (3), a beverage having a good flavor balance can be provided by setting the divisor of the total catechin amount and the caffeine amount in the extract of crude tea to the above values.
(4) 前記荒茶の抽出物中のタンニン量とカフェイン量との除数は、4.5から50である(1)から(3)いずれかに記載の飲料。 (4) The beverage according to any one of (1) to (3), wherein a divisor between the amount of tannin and the amount of caffeine in the crude tea extract is 4.5 to 50.
上記と同様の理由から(4)の発明によれば、荒茶の抽出物中のタンニン量とカフェイン量との除数を上記値としたことによって風味のバランスが良い飲料を提供することができる。 For the same reason as described above, according to the invention of (4), a beverage having a good flavor balance can be provided by setting the divisor between the amount of tannin and the amount of caffeine in the crude tea extract. .
(5) 前記生茶葉は、「べにふうき」、「べにふじ」、「べにほまれ」、「やえほ」、「するがわせ」、「ゆたかみどり」、「かなやみどり」、「おくむさし」、「青心大パン」、「青心烏龍」、「大葉烏龍」、「紅花」、「べにひかり」、「やまかい」、「やまみどり」、「からべに」、「香駿」、「そうふう」及び「おくみどり」もしくはこれらの混合物の茶葉である(1)から(4)いずれかに記載の飲料。 (5) The fresh tea leaves are “Benifuuki”, “Benifuuji”, “Benihore”, “Yaeho”, “Surugasuse”, “Yutaka Midori”, “Kanamidori”, “Okumusashi” ”,“ Blue heart large bread ”,“ Blue heart dragon ”,“ Ooba dragon ”,“ Safflower ”,“ Benihikari ”,“ Yamakai ”,“ Yamamidori ”,“ Karabeni ”,“ Incense ” The beverage according to any one of (1) to (4), which is a tea leaf of “Miso”, “Soufu” and “Okumidori” or a mixture thereof.
(5)の発明によれば、上記の茶葉はカテキン類の中でも抗アレルギー活性が高いメチル化カテキンを含有する茶葉であるため、これらの茶葉を緑茶又は包種茶として用いることによって、カフェイン濃度が低減された状態で抗アレルギー性を有する飲料を提供することが可能となる。また、メチル化カテキンは脂肪の蓄積を抑制するため、脂肪蓄積抑制効果を奏する飲料を提供することができる。なお、メチル化カテキンを含有する茶葉として上記の品種の茶葉を挙げたが、特にこれらの品種に限られるものではない。 According to the invention of (5), since the above tea leaves are tea leaves containing methylated catechins having high antiallergic activity among catechins, the concentration of caffeine can be obtained by using these tea leaves as green tea or seeded tea. It is possible to provide a beverage having anti-allergic properties in a state where the amount of alcohol is reduced. Moreover, since methylated catechin suppresses the accumulation of fat, it can provide a beverage having an effect of inhibiting fat accumulation. In addition, although the tea leaves of the above-mentioned varieties were listed as tea leaves containing methylated catechins, they are not particularly limited to these varieties.
ここで「メチル化カテキン」とは、化学式(1)で示されるものであり、メチル化されたカテキン及び精製の際の不可避成分をいう。本発明におけるメチル化カテキンは主として、エピガロカテキン−3−O−(3−O−メチル)ガレート(以下、EGCG3”Meという)、エピカテキン−3−O−(3−O−メチル)ガレート(以下、ECG3”Meという)、エピカテキン−3−O−(4−O−メチル)ガレート(以下、ECG4”Meという)、エピガロカテキン−3−O−(4−O−メチル)ガレート(以下、EGCG4”Meという)、ガロカテキン−3−O−(3−O−メチル)ガレート(以下、GCG3”Meという)、カテキン−3−O−(3−O−メチル)ガレート(以下、CG3”Meという)、カテキン−3−O−(4−O−メチル)ガレート(以下、CG4”Meという)、又は、ガロカテキン−3−O−(4−O−メチル)ガレート(以下、GCG4”Meという)及びこれらの異性化体を含むことが好ましい。
(6) 茶葉の抽出物を含有する飲料を製造する方法であって、採取した生葉をカフェイン濃度が熱水処理前の60質量%以下、及びシュウ酸又はその塩の濃度が熱水処理前の95質量%以下、になるまで熱水処理を行う工程を有する飲料の製造方法。 (6) A method for producing a beverage containing an extract of tea leaves, wherein the collected fresh leaves have a caffeine concentration of 60% by mass or less before hydrothermal treatment, and the concentration of oxalic acid or a salt thereof before hydrothermal treatment. The manufacturing method of the drink which has the process of performing a hot-water process until it becomes 95 mass% or less.
本発明によれば、採取した生葉に熱水処理を施すことによって、茶葉中のカフェイン含有量、及びシュウ酸又はその塩の含有量を低減させることが可能となる。これにより、だれでも手軽に飲むことができる茶飲料及びその製造方法を提供することができる。またシュウ酸又はその塩は、茶葉においては苦味や、えぐみの成分となるため、シュウ酸又はその塩が選択的に除去されることにより、嗜好性の高い飲料を提供することが可能となる。さらに、上記熱水処理を行なってもカテキン含有量にはほとんど変化がみられなかったことより、使用する茶葉の種類によっては低カフェインで抗アレルギー作用を有する飲料もしくは低カフェインで抗肥満効果を有する飲料を製造することも可能となった。 According to the present invention, it is possible to reduce the content of caffeine in tea leaves and the content of oxalic acid or a salt thereof by subjecting the collected fresh leaves to hot water treatment. Thereby, the tea beverage which anyone can drink easily and its manufacturing method can be provided. In addition, oxalic acid or a salt thereof becomes a bitter taste or an umami component in tea leaves, and therefore, by selectively removing oxalic acid or a salt thereof, it becomes possible to provide a highly palatable beverage. . Furthermore, the catechin content hardly changed even after the above-mentioned hot water treatment, so depending on the type of tea leaves used, it has a low caffeine anti-allergic beverage or a low caffeine anti-obesity effect. It is also possible to produce a beverage having
以下、本発明について詳しく説明する。 The present invention will be described in detail below.
[茶葉の熱水処理]
本発明に係る飲料は、採取した生茶葉中のカフェイン濃度が熱水処理前の60質量%以下であり、かつ、シュウ酸又はその塩の濃度が熱水処理前の95質量%以下、になるまで熱水処理を行なった茶葉の抽出物を用いる。ここで熱水処理とは、茶樹から採取した茶葉(摘採直後から24時間以内の茶葉)に70℃から100℃の熱水を50リットルから250リットル、30秒から180秒間吹き付けることをいう。このときの水圧は茶葉1kgあたり0.01MPaから0.5MPaであることが好ましく、0.08MPaから0.5MPaであることが更に好ましい。
[Hot water treatment of tea leaves]
In the beverage according to the present invention, the concentration of caffeine in the collected fresh tea leaves is 60% by mass or less before the hot water treatment, and the concentration of oxalic acid or a salt thereof is 95% by mass or less before the hot water treatment. Use the tea leaf extract that has been hydrothermally treated until it is. Here, the hot water treatment refers to spraying hot water at 70 ° C. to 100 ° C. for 50 seconds to 250 liters for 30 seconds to 180 seconds on tea leaves collected from tea trees (tea leaves within 24 hours immediately after plucking). The water pressure at this time is preferably from 0.01 MPa to 0.5 MPa, more preferably from 0.08 MPa to 0.5 MPa per kg of tea leaves.
水圧が0.01MPa以下であると、茶葉中のカフェインを低減させることができず、また水圧が0.5MPa以上であっても茶葉中のカフェインを低減させる効果には変化が確認できない。また、水圧が0.5MPa以上であると水圧により茶葉が破砕してしまうことがある。従って、茶葉の外観を損なうことなく、かつ、少ない水量でより効率よく茶葉中のカフェインを低減させるためには、水圧を上記の値の範囲とすることが好ましい。 If the water pressure is 0.01 MPa or less, caffeine in tea leaves cannot be reduced, and even if the water pressure is 0.5 MPa or more, no change can be confirmed in the effect of reducing caffeine in tea leaves. If the water pressure is 0.5 MPa or more, the tea leaves may be crushed by the water pressure. Therefore, in order to reduce caffeine in tea leaves more efficiently with less water amount without impairing the appearance of tea leaves, it is preferable to set the water pressure within the above range.
茶葉の熱水処理は、シャワーの水圧が上記の値となるような条件であればその手段は特に限定されるものではないが、一度に大量の茶葉を処理する場合には、例えば図1に示すようなネットコンベアを有する処理装置1を用いることが好ましい。この処理装置1において茶葉20は、茶葉投入口12から投入された後、熱水処理室10をネットコンベア102により所定の速度で通過していく。このとき、茶葉20は熱水処理室10の天井部分に設けられたシャワー104により熱水処理される。熱水処理された被処理茶葉22は、ネットコンベア102の他端に設けられた茶葉排出口14より排出される。茶葉20の処理時間は、ネットコンベア102の回転速度を調節することにより調節することができる。
The means for the hot water treatment of tea leaves is not particularly limited as long as the water pressure of the shower is the above value, but when treating a large amount of tea leaves at once, for example, FIG. It is preferable to use a
上記の熱水処理により得られた被処理茶葉22を脱水し、その後通常の荒茶の製造工程、即ち蒸熱、粗揉、揉捻、中揉及び精揉工程等を経ることにより荒茶を製造する。なお、実施例において水質についての検討を行なっているが、通常の水を用いても構わない。 The to-be-treated tea leaves 22 obtained by the above hot water treatment are dehydrated, and then the crude tea is produced through the normal production process of rough tea, that is, steaming, rough koji, cocoon twisting, middle koji, and brewing processes. . In addition, although examination about the water quality is performed in the examples, normal water may be used.
また、茶葉の種類は製造する飲料の目的によって適宜選択され、特に限定されるものではない。 Moreover, the kind of tea leaf is appropriately selected depending on the purpose of the beverage to be produced, and is not particularly limited.
[飲料の製造]
本発明に係る飲料は、荒茶を公知の方法で抽出することにより得られる。抽出の際の温度は、溶媒の融点より高く、沸点より低い温度であれば、特に限定されるものではないが、水では10℃から100℃、エタノールおよびメタノールでは10℃から40℃が望ましい。抽出時間は10秒から24時間の範囲とするのが好ましい。
[Manufacture of beverages]
The beverage according to the present invention is obtained by extracting crude tea by a known method. The temperature at the time of extraction is not particularly limited as long as it is higher than the melting point of the solvent and lower than the boiling point, but is preferably 10 ° C. to 100 ° C. for water and 10 ° C. to 40 ° C. for ethanol and methanol. The extraction time is preferably in the range of 10 seconds to 24 hours.
例えば、乾燥させた茶葉を破砕、粉砕等により粉末化処理したものに、抽出溶媒を添加して抽出物又はその処理物として用いることが好ましい。抽出溶媒としては、水;低級アルコール類、例えばメタノール、エタノール、プロパノール、イソプロパノール、ブタノール、イソブタノール;エーテル類、例えばエチルエーテル、ジオキサン;ケトン類、例えばアセトン等が挙げられるが飲料に供するためには、水、エタノール、又は水−エタノール混合溶媒が好ましい。 For example, it is preferable to add an extraction solvent to the dried tea leaves that have been pulverized, pulverized, etc., and used as an extract or a processed product thereof. Examples of the extraction solvent include water; lower alcohols such as methanol, ethanol, propanol, isopropanol, butanol and isobutanol; ethers such as ethyl ether and dioxane; ketones such as acetone and the like. Water, ethanol, or a water-ethanol mixed solvent is preferable.
得られた抽出物は、そのまま飲料として用いてもよいし、他の飲料と混合してもよい。他の飲料と混合するときの抽出物の含有量は、飲料100mL中50mg〜50gであることが好ましい。 The obtained extract may be used as a beverage as it is, or may be mixed with other beverages. The content of the extract when mixed with other beverages is preferably 50 mg to 50 g in 100 mL of beverage.
また、メチル化カテキンを始めとする茶葉中の抗アレルギー成分が十分な抗アレルギー効果を、もしくは茶葉中のカテキン類が十分な脂肪蓄積抑制効果を奏するために、L−アスコルビン酸やアスコルビン酸ナトリウムのような酸化防止剤、香料、各種エステル類、有機酸類、有機酸塩類、無機酸類、無機酸塩類、無機塩類、色素類、乳化剤、保存料、調味料、甘味料、酸味料、果汁エキス類、野菜エキス類、花蜜エキス類、pH調整剤、品質安定剤などの添加剤を単独、あるいは併用して配合してもよい。 In addition, in order for antiallergic components in tea leaves including methylated catechins to have a sufficient antiallergic effect, or catechins in tea leaves to have a sufficient fat accumulation suppressing effect, L-ascorbic acid and sodium ascorbate Such as antioxidants, perfumes, various esters, organic acids, organic acid salts, inorganic acids, inorganic acid salts, inorganic salts, pigments, emulsifiers, preservatives, seasonings, sweeteners, acidulants, fruit juice extracts, Additives such as vegetable extracts, nectar extracts, pH adjusters and quality stabilizers may be used alone or in combination.
例えば甘味料としては、砂糖、ぶどう糖、果糖、異性化液糖、グリチルリチン、ステビア、アスパルテーム、フラクトオリゴ糖、ガラクトオリゴ糖等が挙げられる。酸味料としては、天然成分から抽出した果汁類のほか、クエン酸、酒石酸、リンゴ酸、乳酸、フマル酸、リン酸が挙げられる。クエン酸もしくはリンゴ酸を飲料中に0.1g/Lから5g/L、好ましくは0.5g/Lから2g/L含有するのがよい。酸化防止剤としては、L−アスコルビン酸、L−アスコルビン酸ナトリウム、エリソルビン酸、エリソルビン酸ナトリウム、があげられる。飲料中に、0.005質量%から0.5質量%、好ましくは0.01質量%から0.1質量%含有するのがよい。これによって酸化によって飲料が変色するのを防止することができる。 Examples of sweeteners include sugar, glucose, fructose, isomerized liquid sugar, glycyrrhizin, stevia, aspartame, fructooligosaccharide, and galactooligosaccharide. Examples of acidulants include fruit juices extracted from natural ingredients, citric acid, tartaric acid, malic acid, lactic acid, fumaric acid, and phosphoric acid. Citric acid or malic acid is contained in the beverage in an amount of 0.1 g / L to 5 g / L, preferably 0.5 g / L to 2 g / L. Examples of the antioxidant include L-ascorbic acid, sodium L-ascorbate, erythorbic acid, and sodium erythorbate. It is good to contain 0.005 mass% to 0.5 mass% in a drink, Preferably it is 0.01 mass% to 0.1 mass%. This can prevent the beverage from being discolored by oxidation.
飲料に使用される容器は、一般の飲料と同様にポリエチレンテレフタレートを主成分とする成形容器(いわゆるPETボトル)、密封容器、金属缶、金属箔やプラスチックフィルムと複合された紙容器、瓶などの通常の形態で提供することができる。 Containers used for beverages are molded containers (so-called PET bottles) mainly composed of polyethylene terephthalate, sealed containers, metal cans, paper containers combined with metal foil and plastic films, bottles, etc. It can be provided in the usual form.
また、上記の容器は例えば、金属缶のように容器に充填後、加熱殺菌できる場合にあっては食品衛生法に定められた所定の殺菌条件で製造される。PETボトル、紙容器のようにレトルト殺菌できないものについては、あらかじめ上記と同等の殺菌条件、例えばプレート式熱交換器などで高温短時間殺菌後、一定の温度まで冷却して、容器に充填する等の方法が採用される。また無菌下で、充填された容器に別の成分を配合して充填してもよい。さらに、酸性下で加熱殺菌後、無菌下でpHを中性に戻すことや、中性下で加熱殺菌後、無菌下でpHを酸性に戻すなどの操作も可能である。 Moreover, said container is manufactured on the predetermined | prescribed sterilization conditions prescribed | regulated to the food hygiene law, for example, when it can heat-sterilize after filling a container like a metal can. For PET bottles and paper containers that cannot be sterilized by retort, sterilize under the same conditions as above, for example, sterilize at high temperature and short time in a plate heat exchanger, etc., cool to a certain temperature, and fill the container. The method is adopted. Moreover, you may mix | blend another component with the filled container under aseptic conditions. Furthermore, after sterilization by heating under acidic conditions, the pH can be returned to neutrality under aseptic conditions, or after sterilization by heating under neutral conditions, the pH can be returned to acidic conditions under aseptic conditions.
[茶葉の熱水処理条件]
まず、カフェインを除去するための最適な水質の検討を行なった。図2は、処理水(シャワー水)のpHを変えて処理を行なったときのカフェイン、ストリクチニン及びカテキン類の含有量を示した図である。処理水のpHを3.5〜6.8の間とすることにより、カフェイン除去率が向上することが示された。次に処理水の硬度を変えてカフェインの除去を行なった。その結果を図3に示す。これより軟水を用いた方がカフェインの除去率が向上することが示された。なお、本実施例においてはカフェインの除去効率の検討のために好ましい水質について検討を行なったが、特にこの範囲に限定はされない。
[Heat water treatment conditions for tea leaves]
First, the optimum water quality for removing caffeine was examined. FIG. 2 is a diagram showing the contents of caffeine, strictinin, and catechins when treatment is performed while changing the pH of the treated water (shower water). It was shown that the caffeine removal rate is improved by setting the pH of the treated water to be between 3.5 and 6.8. Next, caffeine was removed by changing the hardness of the treated water. The result is shown in FIG. It was shown that the removal rate of caffeine is improved by using soft water. In addition, although the water quality preferable in order to examine the removal efficiency of caffeine was investigated in the present Example, it does not specifically limit to this range.
[飲料の製造]
茶樹から採取した「べにふうき」(摘採直後から24時間以内の茶葉)25kgから75kgに95℃の熱水50Lから250Lを、所定時間(60秒、90秒、120秒間)吹き付けてシャワーリングした。このときの水圧は茶葉1kgあたり0.1MPaであった。次いで、この被処理茶葉を通常の方法(蒸熱、粗揉、揉捻、中揉及び精揉工程等)により荒茶を製造した。この荒茶を90℃の熱水で抽出し、更にこの抽出物にL−アスコルビン酸ナトリウム、重曹などの副原料を添加してそれぞれ順に試験飲料1から3とした。なお、比較として、採取した生葉を、熱水処理を行なうことなく通常の方法により荒茶を製造して抽出した飲料を試験飲料4とした。
[Manufacture of beverages]
“Benifuuki” (tea leaves within 24 hours immediately after plucking) collected from tea trees was showered by spraying 50 to 250 L of hot water at 95 ° C. for 25 to 75 kg for a predetermined time (60 seconds, 90 seconds, 120 seconds). The water pressure at this time was 0.1 MPa per kg of tea leaves. Next, crude tea was produced from the treated tea leaves by a usual method (steaming, rough koji, cocoon twisting, middle mushrooming, and brewing processes, etc.). This crude tea was extracted with hot water at 90 ° C., and further auxiliary materials such as sodium L-ascorbate and sodium bicarbonate were added to this extract to obtain
[飲料中の化学成分の測定]
上記試験飲料中のカフェイン、カテキン類含有量、含有量の測定を行なった。測定は、液体クロマトグラフ法により分析した。試験飲料は蒸留水で3倍に希釈した。カラムには、和光純薬製(Wakopak Navi C18−5 (4.6×150mm,直径5um))を用い、移動相Aには、水(DW)とアセトニトリルとリン酸(H3PO4)とを体積比400:10:1で混合した溶液を、移動相Bにはメタノールと移動相Aを体積比1:2で混合した溶液を、用いた。測定機器は、島津製作所LC−10Aを用い、オートサンプラは4℃、カラム温度は40℃、注入量は20μl、流速は1ml/min、検出波長はUV272nm、以下の表1に挙げるようなグラジエント条件で分析を行った。なお、グラジエント条件A及びBは測定する化学成分によって適宜変更した。
[Measurement of chemical components in beverages]
Caffeine and catechin content and content in the test beverage were measured. The measurement was analyzed by liquid chromatography. The test beverage was diluted 3 times with distilled water. Wako Pure Chemical (Wakopak Navi C18-5 (4.6 × 150 mm, diameter 5 um)) was used for the column, and water (DW), acetonitrile, phosphoric acid (H 3 PO 4 ) and mobile phase A were used. Was mixed at a volume ratio of 400: 10: 1, and mobile phase B was a solution in which methanol and mobile phase A were mixed at a volume ratio of 1: 2. The measuring instrument is Shimadzu LC-10A, the autosampler is 4 ° C., the column temperature is 40 ° C., the injection volume is 20 μl, the flow rate is 1 ml / min, the detection wavelength is UV 272 nm, and the gradient conditions listed in Table 1 below. The analysis was performed. The gradient conditions A and B were appropriately changed depending on the chemical component to be measured.
試験飲料1から4中のカフェイン、カテキン類含有量、含有量を測定した結果を図4及び図5に示す。また、シュウ酸又はその塩の含有量を測定した結果を図6に示す。これよりシュウ酸等及びカフェインの含有量は、熱水処理時間の増加に伴って減少傾向を示した。特に、カフェインの含有量は50%以下に低減されたものの、メチル化カテキンの含有量にはほとんど変化が確認されなかった。
シュウ酸及びシュウ酸塩の含有量は、以下のように分析した。茶粉砕試料100mgを100mlのメスフラスコに秤量し、蒸留水を80ml加え、80℃で30分間抽出した。これを冷却後、10mMのエチレンジアミン四酢酸二ナトリウム溶液を2.5ml加え、その後蒸留水でフィルアップした。これをよく攪拌した後、上澄み部分をメンブレンフィルタ(アドバンテック、DISMIC−13CP)に通し、分析に供した。また飲料も同じようにメンブレンフィルタを通して分析に供した。シュウ酸の分析はキャピラリー電気泳動法を用いた。すなわち、電気泳動液は10mMクロム酸ナトリウム、0.5mMテトラデシルトリメチルアンモニウムブロミド、0.1mMエチレンジアミン四酢酸二ナトリウムとし、検出波長は254nmで間接吸光度法により分析した。 The contents of oxalic acid and oxalate were analyzed as follows. 100 mg of the ground tea sample was weighed into a 100 ml volumetric flask, 80 ml of distilled water was added, and the mixture was extracted at 80 ° C. for 30 minutes. After cooling this, 2.5 ml of 10 mM ethylenediaminetetraacetic acid disodium solution was added, and then filled up with distilled water. After stirring this well, the supernatant was passed through a membrane filter (Advantech, DISMIC-13CP) for analysis. Similarly, beverages were also analyzed through a membrane filter. Capillary electrophoresis was used for analysis of oxalic acid. That is, the electrophoresis solution was 10 mM sodium chromate, 0.5 mM tetradecyltrimethylammonium bromide, 0.1 mM disodium ethylenediaminetetraacetate, and the detection wavelength was 254 nm and analyzed by the indirect absorbance method.
[官能試験]
官能試験は、試験飲料1から4を飲み比べ、5点満点で採点することによって行なった。その結果を表2に示す。その結果、本発明に係る試験飲料1から3には香味変化は少なく、カフェインによる苦味が抜けたことで、飲みやすくなり、嗜好飲料としても十分な性能を有していることがわかった。
The sensory test was performed by drinking
[ヒスタミン遊離抑制効果の検討]
試験飲料1から4中のヒスタミン遊離抑制効果の検討を行なった。その結果を図7に示す。これより、茶葉に熱水処理を施しても茶葉中の抗アレルギー成分の作用効果に何等の影響を及ぼさないことが示された。
[Study of histamine release inhibitory effect]
The effect of inhibiting histamine release in
なお、抗アレルギー活性(I型アレルギー)の判定法として、マウスマスト細胞からのヒスタミン遊離抑制作用を指標とした。ヒスタミン遊離抑制効果は、マウス骨髄由来培養マスト細胞(BMMC)を用い、10%非働化FBS(牛胎児血清)を3ng/ml、インターロイキン−3(IL−3)、5mMグルタミン酸Naを50μM、2−メルカプトエタノール添加RPMI1640培地で培養した。 In addition, as a method for determining antiallergic activity (type I allergy), an inhibitory action on histamine release from mouse mast cells was used as an index. The inhibitory effect on histamine release is that mouse bone marrow-derived cultured mast cells (BMMC) are used, 10% inactivated FBS (fetal bovine serum) is 3 ng / ml, interleukin-3 (IL-3), 5 mM Na glutamate is 50 μM, 2 -Cultured in RPMI 1640 medium supplemented with mercaptoethanol.
細胞(1×107cells/mL)は、抗DNP−マウスIgE抗体で一晩感作した後、翌日Tyrode液に浮遊させて被検試料とともに10分インキュベート後、DNP−HSA(抗原)を添加して脱顆粒を誘発し(20分)、上清中のヒスタミン量を液体クロマトグラフ法で測定した。 Cells (1 × 10 7 cells / mL) are sensitized overnight with anti-DNP-mouse IgE antibody, then suspended in Tyrode solution the next day and incubated with a test sample for 10 minutes, and then DNP-HSA (antigen) is added. Then, degranulation was induced (20 minutes), and the amount of histamine in the supernatant was measured by liquid chromatography.
測定機器は、島津製作所LC−10Aを用い、カラムはShodex ODP 50−4E、流速は:0.5ml/min、注入量は20μl、カラムオーブン温度は37℃、検出器はRF(ex.330nm, em.430nm)、の条件でイソクラティック分析を行った。抗アレルギー性はコントロールである蒸留水との相対値の低いものほど高いと判断した。 The measuring instrument is Shimadzu LC-10A, the column is Shodex ODP 50-4E, the flow rate is 0.5 ml / min, the injection volume is 20 μl, the column oven temperature is 37 ° C., and the detector is RF (ex. 330 nm, em.430 nm), an isocratic analysis was performed. The antiallergenicity was judged to be higher as the value relative to the control distilled water was lower.
1 処理装置
10 熱水処理室
102 ネットコンベア
104 シャワー
12 茶葉投入口
14 茶葉排出口
20 茶葉
22 被処理茶葉
DESCRIPTION OF
Claims (5)
採取した生葉に、70〜95℃の熱水を、茶葉1kgあたり0.01〜0.5MPaの水圧で60秒〜90秒間にわたって吹き付ける熱水処理を行うことで、カフェイン濃度が熱水処理前の60質量%以下、及びシュウ酸又はその塩の濃度が熱水処理前の95質量%以下である被処理茶葉を得る工程を有する飲料の製造方法。 A method for producing a beverage containing tea leaf extract,
The collected fresh leaves are subjected to hot water treatment in which hot water of 70 to 95 ° C. is sprayed at a water pressure of 0.01 to 0.5 MPa per kg of tea leaves for 60 seconds to 90 seconds, so that the caffeine concentration is before the hot water treatment. The manufacturing method of the drink which has the process of obtaining the to-be-processed tea leaf whose concentration of oxalic acid or its salt is 95 mass% or less before a hot-water process.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005249681A JP4742752B2 (en) | 2005-08-30 | 2005-08-30 | Beverage production method |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005249681A JP4742752B2 (en) | 2005-08-30 | 2005-08-30 | Beverage production method |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2007060957A JP2007060957A (en) | 2007-03-15 |
JP4742752B2 true JP4742752B2 (en) | 2011-08-10 |
Family
ID=37923893
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2005249681A Active JP4742752B2 (en) | 2005-08-30 | 2005-08-30 | Beverage production method |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP4742752B2 (en) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4771088B2 (en) * | 2007-03-01 | 2011-09-14 | 株式会社Riverson | Method for producing tea with reduced caffeine content |
JP5086380B2 (en) * | 2010-01-29 | 2012-11-28 | 株式会社 伊藤園 | Container-packed Hojicha drink |
EA025594B9 (en) * | 2011-06-27 | 2017-08-31 | Унилевер Н.В. | Expressed tea juice and process for producing the same |
JP6027353B2 (en) * | 2012-07-03 | 2016-11-16 | サントリーホールディングス株式会社 | Green tea extract for containerized green tea drink and containerized green tea drink |
JP6438647B2 (en) * | 2013-10-31 | 2018-12-19 | 花王株式会社 | Method for producing green tea extract |
JP6309261B2 (en) * | 2013-12-17 | 2018-04-11 | 花王株式会社 | Method for producing green tea extract |
JP6339907B2 (en) * | 2014-09-12 | 2018-06-06 | 松浦薬業株式会社 | Kampo jelly pharmaceutical composition |
JP6598460B2 (en) * | 2014-12-25 | 2019-10-30 | 花王株式会社 | Method for producing green tea extract |
CN105494823A (en) * | 2015-12-31 | 2016-04-20 | 中国土产畜产进出口总公司 | Device for removing caffeine in tea leaf |
WO2018100947A1 (en) | 2016-11-29 | 2018-06-07 | 花王株式会社 | Production method for composition which contains non-polymer catechin |
KR102428987B1 (en) * | 2017-05-16 | 2022-08-04 | (주)아모레퍼시픽 | Composition Containing Extracts of Camellia sinensis |
JP6831616B2 (en) * | 2017-12-22 | 2021-02-17 | 株式会社 伊藤園 | Manufacturing method of edible tea leaves |
JP2021058219A (en) * | 2021-01-19 | 2021-04-15 | 花王株式会社 | Production method for composition containing non-polymer catechins |
JP7057986B1 (en) | 2021-11-19 | 2022-04-21 | 株式会社ひかわ | Tea leaf processing device, tea leaf processing method |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH07135902A (en) * | 1992-10-27 | 1995-05-30 | Terada Seisakusho:Kk | Method for heat-treating tea leaf and device therefor |
JP4536581B2 (en) * | 2005-04-25 | 2010-09-01 | 株式会社寺田製作所 | Tea leaves low caffeine processing equipment |
-
2005
- 2005-08-30 JP JP2005249681A patent/JP4742752B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
JP2007060957A (en) | 2007-03-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4742752B2 (en) | Beverage production method | |
TWI328428B (en) | Packaged beverages | |
KR100842634B1 (en) | Physiologically functional drinks and compositions | |
JP4884003B2 (en) | Container oolong tea drink | |
JP2017079674A (en) | Packed tea beverage | |
JP4940047B2 (en) | Container drink | |
JP6309214B2 (en) | Roasted tea beverage | |
JP4838784B2 (en) | Container drink | |
JP2010193831A (en) | Container-packed beverage | |
KR101627541B1 (en) | Roasted green tea drink packed in container | |
JP2009112302A (en) | Beverage | |
JP5820681B2 (en) | Bitter taste inhibitor | |
JP6133008B2 (en) | How to control obesity | |
JP6310625B1 (en) | Beverages containing tiliroside and chlorogenic acids | |
KR102400682B1 (en) | beverage composition | |
JP4819005B2 (en) | Manufacturing method for packaged tea beverages | |
WO2012086709A1 (en) | Method for suppressing bitterness | |
JP7204031B1 (en) | Tannin-containing beverage | |
JP7407643B2 (en) | Heat-sterilized packaged beverage containing medium-chain fatty acid triglyceride and ascorbic acid | |
JP6782865B2 (en) | Containered tea beverage | |
JP5744471B2 (en) | Bitter taste inhibitor | |
KR101390366B1 (en) | Manufacturing Method of Extract from Bulnesia Sarmienti containing Catechins, Extract from Bulnesia Sarmienti manufactured by the same, High Catechins Granular Tea containing the same and Food Composition for removing active oxygen, obesity control, body fat reduction containing the same | |
JP6895762B2 (en) | A packaged hesperidin-containing beverage in which the offensive odor of hesperidin enhanced by the combined use of hesperidin and a high-intensity sweetener is suppressed. | |
JP7138412B2 (en) | Bitter taste suppressant, food composition, pharmaceutical composition, kit for suppressing bitter taste, and method for suppressing bitter taste | |
JP2016189729A (en) | Packed tea beverage suppressed in reduction and generation of astringent |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20080818 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080904 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20100726 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100803 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20101001 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20110419 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20110425 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140520 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 4742752 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
S533 | Written request for registration of change of name |
Free format text: JAPANESE INTERMEDIATE CODE: R313533 |
|
S533 | Written request for registration of change of name |
Free format text: JAPANESE INTERMEDIATE CODE: R313533 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313117 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |